SeekingAlpha · Aug 30, 2026
Fortrea Holdings: The Turnaround Is Showing Up In Earnings Before Revenue
Fortrea is rated Buy near $18.86 on a cost-cut-driven earnings turnaround. Click for more on FTRE stock.
FT
NASDAQ · FTRE
Fortrea Holdings Inc.
Healthcare · Biotechnology
$17.70
Down-$0.92 (-4.94%)
Updated Sep 6, 2026, 7:16 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.4B
- P/E ratio
- -1.4
- Dividend yield
- 0.00%
- 52-week range
- $8.31 – $21.39
- Volume
- 762.08K
- Avg. volume
- 1.34M
Price performance
FTRE price history
1M range · 20 trading sessions · Daily adjusted prices
FTRE closed at $17.70 after 20 trading sessions, down 6.79% for the selected period.
- Last close
- $17.70
- Period change
- -6.79%
- Period low
- $17.41
- Period high
- $19.52
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $18.50 | $18.50 | $17.64 | $17.70 | 762.08K |
| Sep 3, 2026 | $18.67 | $18.99 | $18.18 | $18.62 | 776.31K |
| Sep 2, 2026 | $17.91 | $19.00 | $17.81 | $18.36 | 902.45K |
| Sep 1, 2026 | $18.38 | $18.51 | $17.62 | $17.72 | 1.19M |
| Aug 31, 2026 | $18.60 | $18.77 | $18.02 | $18.37 | 1.51M |
| Aug 28, 2026 | $18.765 | $19.14 | $18.46 | $18.81 | 1.14M |
| Aug 27, 2026 | $18.70 | $19.34 | $18.55 | $18.86 | 1.32M |
| Aug 26, 2026 | $18.10 | $18.55 | $17.99 | $18.53 | 598.3K |
| Aug 25, 2026 | $18.33 | $18.64 | $17.87 | $18.27 | 599.53K |
| Aug 24, 2026 | $18.34 | $18.45 | $17.78 | $18.31 | 1.05M |
| Aug 21, 2026 | $18.23 | $18.539 | $17.82 | $18.39 | 864.12K |
| Aug 20, 2026 | $17.88 | $18.765 | $17.87 | $18.19 | 1.52M |
| Aug 19, 2026 | $17.93 | $18.49 | $17.8675 | $18.14 | 1.03M |
| Aug 18, 2026 | $17.80 | $18.10 | $17.405 | $17.60 | 682.08K |
| Aug 17, 2026 | $17.37 | $18.12 | $17.15 | $18.10 | 1.15M |
| Aug 14, 2026 | $17.65 | $17.84 | $16.84 | $17.41 | 2.56M |
| Aug 13, 2026 | $18.52 | $18.68 | $17.71 | $17.82 | 1.33M |
| Aug 12, 2026 | $19.33 | $19.35 | $18.30 | $18.33 | 1.66M |
| Aug 11, 2026 | $18.94 | $19.585 | $18.82 | $19.52 | 869.37K |
| Aug 10, 2026 | $18.12 | $19.285 | $17.91 | $18.99 | 1.04M |
Latest FTRE news
The latest Smart Investors Daily articles mentioning FTRE.
Stock researchCompany · Overview
FTRE research
Overview
Company profile and research snapshot.
Company profile
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | TD Cowen | Buy | — |
| Jul 31, 2026 | Citigroup | Buy | — |
| Jul 30, 2026 | Truist Securities | Buy | — |
| Jul 30, 2026 | Evercore ISI Group | Outperform | — |
| Jul 30, 2026 | Barclays | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 15, 2026
Drug Development Inputs & Services Stocks Q2 In Review: Fortrea (NASDAQ:FTRE) Vs Peers
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Fortrea (NASDAQ:FTRE) and the best and worst performers in the drug development inputs & services industry.
Yahoo · Aug 13, 2026
This Healthcare Services Stock Has 37% Upside
Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.
Yahoo · Aug 11, 2026
Fortrea (FTRE) Gains Traction in Turnaround
Investment management company Curreen Capital released its second-quarter 2026 Investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned 22.26% compared to 15.20% for the S&P 500 Index. The performance was driven by active special case investments, including buying a tender offer, a merger-spinoff, and investments in […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
